Compare Natco Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA CIPLA NATCO PHARMA/
CIPLA
 
P/E (TTM) x 31.6 29.1 108.6% View Chart
P/BV x 4.5 4.1 109.2% View Chart
Dividend Yield % 0.8 0.5 151.1%  

Financials

 NATCO PHARMA   CIPLA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
CIPLA
Mar-20
NATCO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs849586 145.0%   
Low Rs557357 156.1%   
Sales per share (Unadj.) Rs573.8207.0 277.2%  
Earnings per share (Unadj.) Rs176.018.6 946.4%  
Cash flow per share (Unadj.) Rs198.233.2 597.6%  
Dividends per share (Unadj.) Rs6.254.00 156.3%  
Dividend yield (eoy) %0.90.8 104.7%  
Book value per share (Unadj.) Rs842.7195.5 431.1%  
Shares outstanding (eoy) m36.50806.35 4.5%   
Bonus/Rights/Conversions BBESOS-  
Price / Sales ratio x1.22.3 53.8%   
Avg P/E ratio x4.025.3 15.8%  
P/CF ratio (eoy) x3.514.2 25.0%  
Price / Book Value ratio x0.82.4 34.6%  
Dividend payout %3.621.5 16.5%   
Avg Mkt Cap Rs m25,660379,912 6.8%   
No. of employees `0005.025.8 19.2%   
Total wages/salary Rs m3,55930,270 11.8%   
Avg. sales/employee Rs Th4,225.36,459.6 65.4%   
Avg. wages/employee Rs Th718.01,171.2 61.3%   
Avg. net profit/employee Rs Th1,295.9580.2 223.4%   
INCOME DATA
Net Sales Rs m20,945166,949 12.5%  
Other income Rs m1,3023,442 37.8%   
Total revenues Rs m22,247170,391 13.1%   
Gross profit Rs m7,94832,060 24.8%  
Depreciation Rs m81011,747 6.9%   
Interest Rs m1931,974 9.8%   
Profit before tax Rs m8,24721,782 37.9%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8236,312 28.9%   
Profit after tax Rs m6,42414,995 42.8%  
Gross profit margin %37.919.2 197.6%  
Effective tax rate %22.129.0 76.3%   
Net profit margin %30.79.0 341.5%  
BALANCE SHEET DATA
Current assets Rs m23,472117,038 20.1%   
Current liabilities Rs m7,28743,931 16.6%   
Net working cap to sales %77.343.8 176.5%  
Current ratio x3.22.7 120.9%  
Inventory Days Days9296 96.3%  
Debtors Days Days8885 103.7%  
Net fixed assets Rs m18,648107,424 17.4%   
Share capital Rs m3651,613 22.6%   
"Free" reserves Rs m34,525156,018 22.1%   
Net worth Rs m30,760157,630 19.5%   
Long term debt Rs m023,693 0.0%   
Total assets Rs m43,031236,626 18.2%  
Interest coverage x43.712.0 363.3%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.50.7 69.0%   
Return on assets %15.47.2 214.4%  
Return on equity %20.99.5 219.5%  
Return on capital %27.412.8 213.7%  
Exports to sales %033.0 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,53656,036 20.6%   
Fx outflow Rs m2,9396,764 43.4%   
Net fx Rs m8,59749,272 17.4%   
CASH FLOW
From Operations Rs m6,68830,685 21.8%  
From Investments Rs m-6,1221,040 -588.4%  
From Financial Activity Rs m-509-29,488 1.7%  
Net Cashflow Rs m662,340 2.8%  

Share Holding

Indian Promoters % 52.0 16.0 325.3%  
Foreign collaborators % 1.5 20.8 7.1%  
Indian inst/Mut Fund % 7.8 12.2 64.3%  
FIIs % 16.6 23.7 70.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.0 26.2 99.2%  
Shareholders   25,395 161,166 15.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  ALEMBIC  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - DISHMAN PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS